Objectives: Extended-spectrum beta-lactamase (ESBL)-producing bacteria often causes bacteremia, leading serious outcomes. In this study, we conducted a retrospective analysis to identify the risk factors associated with death by bacteremia of ESBL-producing bacteria. Methods: Patients with bacteremia by ESBL-producing bacteria were retrospectively collected in Kobe University Hospital, Japan, between January 2011 and December 2015. Potential risk factors for death caused by ESBL-bacteremia were analyzed for patients’ outcome (recovery or death) by univariate and multivariate analysis. Results: A total of 101 patients (64 male and 37 female) were recruited. The most frequently detected ESBL-producing bacteria were Escherichia coli (91 cases; 90.1%), followed by Klebsiella pneumoniae (8 cases; 7.9%). Most frequently used antibiotics after the detection of bacteremia was meropenem (66.3%; 67/101) followed by cefmetazole (51.5%; 52/101). Univariate analysis showed a significantly positive correlation with mortality in ICU admission (p < 0.001), circulatory diseases (p = 0.022), shock (p = 0.044), and respirator requirement (p = 0.002). Multivariate analysis showed ICU admission remained significant risk factor for mortality (p = 0.0192). Conclusions: We showed ICU admission was significantly correlated with death from bacteremia by ESBL-producing bacteria. These factors should be monitored to estimate severity of ESBL causing-bacteremia for better patients’ outcomes.

Keywords:
Risk factors, Infection, Urinary tract infection
1.
Pitout JD: Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010; 70: 313–333.
2.
Ishii Y, Ohno A, Taguchi H, Imajo S, Ishiguro M, Matsuzawa H: Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A beta-lactamase isolated from Escherichia coli. Antimicrob. Agents Chemother 1995; 39: 2269–2275.
3.
Gudiol C, Calatayud L, Garcia-Vidal C, et al: Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J. Antimicrob Chemother 2010; 65: 333–341.
4.
Peralta G, Sánchez MB, Garrido JC, et al: Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J. Antimicrob Chemother 2007; 60: 855–863.
5.
Marchaim D, Gottesman T, Schwartz O, et al: National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2010; 54: 5099–5104.
6.
Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME: Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012; 67: 2793–2803.
7.
Kang CI, Kim SH, Kim DM, et al: Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum b-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2004; 25: 860–867.
8.
Du B, Long Y, Liu H, et al: Extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 2002; 28: 1718–1723.
9.
Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH: Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator associated pneumonia. Chest 2002; 122: 262–268.
10.
Tumbarello M, Spanu T, Sanguinetti M, et al: Bloodstream infections caused by extended-spectrum-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006; 50: 498–504.
11.
Sahly H, Aucken H, Benedi VJ, et al: Increased serum resistance in Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2004; 48: 3477–3482.
12.
Ho PL, Chan WM, Tsang KT, Wong SS, Young K: Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes. Scand J Infect Dis 2002; 34: 567–573.
13.
Kang CI, Kim SH, Park WB, et al: Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004; 48 4574–4581.
14.
Frakking FNJ, Rottier WC, Dorigo-Zetsma JW, et al: Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria. Antimicrob Agents Chemother 2013; 57: 3092–3099.
15.
Wagenlehner FM, Lichtenstern C, Rolfes C, et al: Diagnosis and management for urosepsis. Int J Urol 2013; 20: 963–970.
16.
Osawa K, Shigemura K, Shimizu R, et al: Molecular characteristics of extended-spectrum β-lactamase-producing Escherichia coli in a university teaching hospital. Microb Drug Resist 2015; 21: 130–139.
17.
Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing; 20th Informational Supplement (M100-S20). Wayne, Clinical and Laboratory Standards Institute, 2010.
18.
Paterson DL, Ko WC, Von Gottberg A, et al: International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004; 140: 26–32.
19.
Kang CI, Song JH, Chung DR, et al: Korean Network for Study of Infectious Diseases (KONSID). Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli. Int J Antimicrob Agents 2010; 36: 284–287.
20.
Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y: Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006; 50: 1257–1262.
21.
Medina-Polo J, Arrébola-Pajares A, Pérez-Cadavid S, et al: Extended-spectrum beta-lactamase-producing bacteria in a urology ward: epidemiology, risk factors and antimicrobial susceptibility patterns. Urol Int 2015; 95: 288–292.
22.
Paterson DL, Ko WC, Von Gottberg A, et al: Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39: 31–37.
23.
Fukuchi T, Iwata K, Kobayashi S, Nakamura T, Ohji G: Cefmetazole for bacteremia caused by ESBL-producing Enterobacteriaceae comparing with carbapenems. BMC Infect Dis 2016; 16: 427.
24.
Melzer M, Petersen I: Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007; 55: 254–259.
25.
Chaubey VP, Pitout JD, Dalton B, et al: Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. BMC Res Notes 2010; 3: 116.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.